Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular...
Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular...
The word ‘acquisition’ typically is one of the biggest catalysts for shares of publicly traded companies. Tuesday’s premarket is currently proving this theory To read the full...
Acquisition further strengthens Rocket’s leadership in AAV-based cardiac gene therapy and expands Company’s near-term clinical assets for the treatment of heart conditions Significant unmet...
Biotech is getting some attention this week as healthcare stocks seem to be outperforming major indices. Just today, a certain Connecticut-based biotech turned heads after BTIG To read the full...
REN-001 IND submission planned for the second half of 2022 Data from pilot pig study showing successful cardiac transduction with REN-001 delivered via low-dose retrograde coronary sinus...
Research collaboration with the University of Utah's Nora Eccles Harrison Cardiovascular Research and Training Institute expands pipeline with the addition of an AAV gene therapy program for...
REN-001 delivered locally via low-dose retrograde coronary sinus infusion demonstrated robust, diffuse cardiomyocyte transduction in a large animal heart Renovacor, Inc. (NYSE: RCOR), a...
REN-001 advancing toward IND submission in the second half of 2022 with the initiation of a Phase I/II clinical trial in BAG3-DCM expected thereafter Strengthened executive team with appointment...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.